Magazine
#6 Genzyme Corp.
500 Kendall St.
Cambridge, MA 02142
Tel: (617) 252-7500
Fax: (617) 252-7600
www.genzyme.com
| Headcount | 8,000+ | |
| Year Established | 1981 | |
| Biopharma Revenues | $1,773 | +20% |
| Total Revenues | $2,734 | +24% |
| Net Income | $441 | +407% |
| R&D Budget | $503 | +29% |
| Drugs Approved/Launched |
|
| Drug | Indication |
| myozyme |
Pompe disease |
| Drugs in Phase IIb and Beyond | |
| Drug | Indication |
| campath |
multiple sclerosis |
| deferitrin |
iron overload diseases |
| genz-112638 |
Gaucher disease |
| sevelamer carbonate | end-stage renal disease, chronic kidney disease |
| bio-replacement therapy | acute renal failure |
| tolevamer | C. difficile-associated diarrhea |
| thyrogen | ablation of thyroid cancer |
| dx-88 | hereditary angioedema |
| thymoglobulin | living kidney donor, liver transplant |
| clolar | adult acute myeloid leukemia |
| tasidotin | melanoma, lung and prostate cancer |
| gene therapy | peripheral arterial disease |
| hylastan |
new formulation |
| Early Research Projects |
|
| Drug | Indication |
| gene therapy |
Parkinson’s disease |
| gc 1008 |
pulmonary fibrosis, solid tumors |
| Fc receptor antagonist |
idiopathic thrombocytopenic purpura |
| thymoglobulin |
type 1 diabetes |
| acid sphingomyelinase |
type B Niemann Pick disease |
| anti-TGF beta |
kidney sclerosis |
| N gene therapy | age-related macular degeneration |
| thymoglobulin |
type 1 diabetes |
| Top Selling Drugs |
|||
| Drug | Indication |
Sales |
(+/-%) |
| cerezyme |
Gaucher disease |
$932 | +11% |
| renagel | hemodialysis | $417 | +15% |
| fabrazyme |
Fabry disease |
$305 | +45% |
| hectorol |
renal disease |
$35 | n/a |
Account for 95% of total biopharma sales, down from 96% in 2004.
PROFILE
Genzyme, which recently celebrated its 25th anniversary, has reason to top off the champagne with its recent approval of Myozyme. The company won approval in both the U.S. and E.U. to sell the drug, the first treatment ever for Pompe disease, a rare enzyme-deficiency disorder that causes extreme muscle damage and heart failure. Genzyme's current pipeline momentum is steady. It seems developing drugs for so-called "neglected" diseases with relatively small patient populations, is paying off.
Two drugs moving down the pipeline include Campath in Phase II development for the treatment of multiple sclerosis and DX-88 in Phase III development for hereditary angioedema (HAE) a rare genetic disease. Genzyme also acquired extensive gene therapy assets from Avigen, Inc., including a development program in Parkinson's disease, and a clinical collaboration in hemophilia. The company's gene therapy research program now includes work in cardiovascular disease, lysosomal storage disorders, among other conditions.
In 2005, the company focused on its facilities and manufacturing expertise for its antibody and protein-based products. Genzyme made several investments, acquiring viral manufacturing facilities from Cell Genesys and spending $3.2 million to acquire a manufacturing facility that will make several gene therapy treatments. Additionally, Genzyme expanded its research and manufacturing presence in Massachusetts with the construction of a new research facility in Waltham and a major expansion of its protein manufacturing facility in Allston. Genzyme has substantially expanded its global infrastructure as well for both manufacturing and development through four major projects in Belgium, Ireland, and the UK.
Overall, 2005 was a productive year for the company and earnings were up an impressive 408% to $442 million. What's ahead for Genzyme? Performance in the first quarter 2006 reflects a similar growth trend with revenue up 16% to $731 million. Big contributors were Renagel with sales reaching $119 million and Hectorol sales that reached $18.9 million—which would have been $3 million higher, were it not for a non-recurring contractual allowance charge. Also, there were notable increases for Aldurazyme and Thyrogen, up 34% to $21 million and 30% to $23 million, respectively. Synvisc also has a lot of potential in 2006 with sales up 21% in the first quarter to $53 million. Gene therapy is definitely on the up and up. -—KB
